Thomas, McNerney &a; Partners is a health care venture capital firm with approximately $600 million under management focused on investing in
Business Model:
Revenue: $14.3M
Employees: 11-50
Address: 263 Tresser Blvd 9th Floor
City: Stamford
State: CT
Zip: 06901
Country: US
Thomas, McNerney &a; Partners is a health care venture capital firm with approximately $600 million under management focused on investing in life science and medical technology companies. The firm targets investments in the pharmaceutical, medical device, biotechnology and diagnostic sectors as well as in other areas utilizing medical technology innovation. Companies developing therapeutic products for life threatening or costly, chronic conditions are of particular interest. Thomas, McNerney &a; Partners invests in companies at all stages of their development. In addition to helping entrepreneurs launch companies with seed and early stage funding, the firm provides growth capital to emerging companies to advance clinical development or for product commercialization. The partnership also is involved in spinning out products and divisions from major medical device and pharmaceutical companies, consolidating companies through roll-up strategies and participating in structured financings for public companies as well as recapitalizations.
Contact Phone:
+12039782010
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
3/2017 | VertiFlex | Equity | 45.3M |
10/2009 | Quinnova Pharmaceuticals | Series B | 17.4M |
12/2006 | Softscope Medical Technologies | Series A | 4M |
7/2010 | Zogenix | Venture Round | 0 |
4/2012 | Tioga Pharmaceuticals | Series B | 10M |
2/2010 | Altair Therapeutics | Series B | 17M |
11/2007 | Tranzyme | Venture Round | 20M |
8/2003 | Coley Pharmaceutical Group | Series F | 30M |
2/2004 | Clarus Therapeutics | Series A | 2.5M |
3/2006 | Clarus Therapeutics | Series B | - |
2/2008 | Ocera Therapeutics | Series C | 0 |
10/2003 | OsteoBiologics | Venture Round | 9.2M |
7/2016 | Torax Medical | Series E | 0 |
2/2011 | VertiFlex | Venture Round | 14M |
8/2007 | Leptos Biomedical | Series C | 20M |
6/2011 | CAS Medical Systems | Post-IPO Equity | 15M |
12/2006 | Galil Medical | Venture Round | 52M |
1/2013 | AxioMed Spine | Series D | 0 |
3/2009 | Atritech | Venture Round | 0 |
12/2006 | Elron Ventures | Post-IPO Equity | 52M |
9/2014 | SG Biofuels | Series C | 11M |
2/2005 | AxioMed Spine | Series B | 18M |
10/2010 | AxioMed Spine | Series D | 0 |
1/2012 | SG Biofuels | Series B | 17M |
4/2009 | Torax Medical | Series C | 15M |
11/2012 | Auspex Pharmaceuticals | Series D | 0 |
6/2005 | Torax Medical | Series B | 10M |
7/2005 | Solstice Neurosciences | Venture Round | 8M |
9/2010 | Celator Pharmaceuticals | Series D | 0 |
7/2006 | Ocera Therapeutics | Series B | 12M |
10/2010 | Auspex Pharmaceuticals | Series C | 12M |
1/2014 | Auspex Pharmaceuticals | Series E | 0 |
8/2006 | Zogenix | Series A | 60M |
9/2010 | Cebix | Venture Round | 16M |
10/2012 | Cebix | Series B | 0 |
10/2014 | Invitae | Series F | 0 |
11/2007 | Clarus Therapeutics | Series C | 8M |
9/2004 | Coley Pharmaceutical Group | Series G | 25.2M |
11/2009 | Virdante Pharmaceuticals | Series A | 30M |
5/2010 | Ntprx | Series B | 43M |
1/2010 | Intuity Medical | Series D | 64M |
1/2004 | Intuity Medical | Series B | 0 |
9/2012 | Torax Medical | Series D | 0 |
11/2006 | Solstice Neurosciences | Series B | 85M |
11/2006 | Quinnova Pharmaceuticals | Series A | 13.6M |
5/2005 | Tranzyme | Series A | - |
12/2011 | InnoPharma | Series A | 15M |
8/2006 | Intuity Medical | Series C | 20M |
3/2017 | VertiFlex | Venture Round | 0 |
7/2016 | Torax Medical | Series E | 0 |
10/2014 | Invitae | Series F | 0 |
9/2014 | SG Biofuels | Series C | 0 |
1/2014 | Auspex Pharmaceuticals | Series E | 0 |
1/2013 | AxioMed Spine | Series D | 0 |
11/2012 | Auspex Pharmaceuticals | Series D | 0 |
10/2012 | Cebix | Series B | 0 |
9/2012 | Torax Medical | Series D | 0 |
4/2012 | Tioga Pharmaceuticals | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|